Showing results (101-110 of 116) with videos related to
Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeO Michielin, A van Akkooi, P Lorigan, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeU Keilholz, P A Ascierto, R Dummer, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 16, 2020
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countriesL Kandolf-Sekulovic, K Peris, A Stratigos, et al.BMC Cancer|March 26, 2021
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trialE E A P Mulder, K de Joode, S Litière, et al.European Journal of Cancer (Oxford, England : 1990)|March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatmentsL Kandolf Sekulovic, K Peris, A Hauschild, et al.European Journal of Cancer (Oxford, England : 1990)|November 3, 2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countriesL Kandolf Sekulovic, J Guo, S Agarwala, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanomaK C Kähler, J C Hassel, M Ziemer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2014
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†C A Bellera, N Penel, M Ouali, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.Pageof 12